Attached files

file filename
10-K - FORM 10-K - Marker Therapeutics, Inc.form10-k.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 RULE 13A-14(A) OR 15D-14(A) - Marker Therapeutics, Inc.exhibit31-1.htm
EX-31.2 - CERTIFICATION OF ACTING PRINCIPAL ACCOUNTING OFFICER PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 RULE 13A-14(A) OR 15D-14(A) - Marker Therapeutics, Inc.exhibit31-2.htm
EX-32.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 - Marker Therapeutics, Inc.exhibit32-1.htm
 
 



 
Exhibit 32.2
 
CERTIFICATION OF ACTING PRINCIPAL ACCOUNTING OFFICER
 
PURSUANT TO 18 U.S.C. SECTION 1350,
 
AS ADOPTED PURSUANT TO
 
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
The undersigned, Tracy A. Moore, the Acting Principal Accounting Officer of TapImmune Inc. (the “Company”), hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his or her knowledge, the Annual Report on Form 10-K for the year ended December 31, 2009 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Annual Report on Form 10-K, as amended, fairly presents in all material respects the financial condition and results of operations of the Company.
 
Date: April 13, 2010
 
By:          /s/ Tracy Moore________________________
Tracy A. Moore
Secretary, Treasurer, Chief Financial Officer,
Acting Principal Accounting Officer and a director